(Q46727883)

English

Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis--results of a retrospective multicenter observational study over five years

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16193894

Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis--results of a retrospective multicenter observational study over five years (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16193894

multiple sclerosis

0 references

relapsing-remitting multiple sclerosis

0 references

author name string

J Haas

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16193894

M Maas-Enriquez

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16193894

H-P Hartung

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16193894

publication date

1 October 2005

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16193894

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16193894

11

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16193894

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16193894

562-567

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16193894

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy.

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

Multiple sclerosis

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

The natural history of multiple sclerosis: implications for trial design

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

New concepts in the immunopathogenesis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, March 2002

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS study

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment.

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

Which clinical studies provide the best evidence? The best RCT still trumps the best observational study

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

A comparison of observational studies and randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

Randomized, controlled trials, observational studies, and the hierarchy of research designs

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1224OA

21 January 2018

Identifiers

10.1191/1352458505MS1224OA

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16193894

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16193894

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46727883&oldid=2128498070"